MRS 2957 triethylammonium salt
Cat. No. 4260
Chemical Name: P1-[5'(N4-Methoxycytidyl)]-P3-(5'-uri
Biological ActivityPotent P2Y6 agonist (EC50 = 12 nM). Displays 14- and 66-fold selectivity against P2Y2 and P2Y4 receptors respectively.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Maruoka et al (2010) Pyrimidine ribonucleotides with enhanced selectivity as P2Y6 receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate γ-ester modifications. J.Med.Chem. 53 4488. PMID: 20446735.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for MRS 2957 triethylammonium salt include:
Balasubramanian et al (2014) Enhancement of glucose uptake in mouse skeletal muscle cells and adipocytes by P2Y6 receptor agonists. Nat Methods 9 e116203. PMID: 25549240.
Do you know of a great paper that uses MRS 2957 triethylammonium salt from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: MRS 2957 triethylammonium salt, supplier, MRS2957, triethylammonium, salt, potent, selective, purinergics, purines, purinoceptors, p2y6, agonists, Tocris Bioscience, Purinergic (P2Y) Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Highly potent P2Y12 antagonistFTY 720
Potent S1P receptor agonist; also immunosuppresentCinacalcet hydrochloride
Calcium-sensing receptor (CaSR) allosteric agonist; also CYP2D2 inhibitor and Ca2+ channel blocker; orally bioavailableAMG 837 hemicalcium salt
Potent free fatty acid receptor 1 (FFA1/GPR40) partial agonistUMB 68
GHB receptor ligandAZD 1283
High affinity P2Y12 antagonistEx 26
Potent and selective S1P1 receptor antagonistZQ 16
Selective GPR84 agonistIHR-Cy3
Potent fluorescent Smo antagonistRo 6842262
Potent LPA1 antagonistAMG 853
Potent dual CRTH2 and prostaglandin D2 (PGD2) receptor antagonistAM 4668
Potent FFA1 (GPR40) agonist
April 22 - 26, 2017
Chicago, IL, USA